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Abstract
Background: This study is an analysis of the prevalence of polymorphous low grade adenocarcinoma (PLGA) in
epidemiological surveys of salivary tumors published in the English language from 1992 to 2012.
Methods: These surveys included studies from different researchers, countries and continents. The 57 surveys for
which it was possible to calculate the percentage of PLGAs among all malignant minor salivary gland tumors
(MMSGT) were included in this review.
Results: The statistical analyses show significant differences in the PLGA percentage by time period, country and
continent in the studies included in this review. The percentage of PLGAs among MMSGTs varied among the
studies, ranging from 0.0% to 46.8%. PLGA rates have varied over the period studied and have most recently
increased. The frequency of reported PLGA cases also varied from 0.0% to 24.8% by the country in which the
MMSGT studies were performed. The PLGA percentages also varied significantly by continent, with frequencies
ranging from 3.9% in Asia to 20.0% in Oceania
Conclusion: Based on these results, we concluded that although the accuracy of PLGA diagnoses has improved,
they remain a challenge for pathologists. To facilitate PLGA diagnoses, we have therefore made some suggestions
for pathologists regarding tumors composed of single-layer strands of cells that form all of the histological patterns
present in the tumor, consistency of the cytological appearance and uniformly positive CK7, vimentin and S100
immunohistochemistry, which indicate a single PLGA phenotype.
Virtual slide: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1059098656858324
Keywords: Polymorphous low-grade adenocarcinoma, Epidemiological review, Diagnosis hints
Introduction
Polymorphous low-grade adenocarcinoma (PLGA) is a
malignant epithelial tumor characterized by cytological
uniformity, morphological diversity, an infiltrative growth
pattern and low metastatic potential [1]. This tumor was
recognized as a distinct entity in 1983 by Freedman and
Lumerman and Batsakis et al., and it was named poly-
morphous low-grade adenocarcinoma by Evans and Batsa-
kis in 1984 [2-4].
Clinically PLGA presents as an indolent asymptomatic
swelling but occasionally can be painful and even ulcer-
ate. The most common location of PLGA is the palate,
although other locations have been described. It occurs
more frequently in women affecting mainly the sixth
and seventh decade of life. For more details on clinical
presentation, prognosis and treatment, we recommend
the reviews by Pogodzinski et al., and Paleri, Robinson
and Bradley [5,6]. In general these authors indicate a low
grade malignancy and good prognosis of this tumor
They also recommend a very careful and systematic
follow- up,since recurrences and rare metastases can
occur many years after the surgery.
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Table 1 The distribution of salivary gland tumors, minor salivary gland tumors and polymorphous low-grade
adenocarcinoma in the studies included in this review
Author Year Country SGTs MSGTs MMSGTs PLGAs
n n % in relation to
SGTs
n % in relation to
Minor SGTs
n % in relation
to MMSGTs
Onyango et al. 1992 Kenya 417 189 45.3 58 30.7 0 —
Rippin e Potts 1992 England 194 194 — 88 45.4 0 —
Loyola et al. 1995 Brazil 164 164 — 65 39.6 4 6.2
Neely et al. 1996 USA 106 106 — 47 44.3 22 46.8
Rivera-Bastidas et al. 1996 Venezuela 62 62 — 28 45.2 0 —
Rushing et al. 1996 USA 277 27 9.7 16 59.3 0 —
Kusama et al. 1997 Japan 129 129 — 49 38.0 —
Nagler et al. 1997 Israel 245 67 27.3 33 49.3 3 9.1
Jones et al. 1998 England 145 145 — 103 71.0 —
Lopes et al. 1999 Brazil 196 196 — 129 65.8 3 2.3
Maaita et al. 1999 Jordan 221 42 19.0 20 47.6 0 —
Pacheco-Ojeda et al. 2000 Ecuador 308 28 9.1 14 50.0 0 —
Koivunen et al. 2002 Finland 40 4 10.0 4 — 0 —
Vargas et al. 2002 Brazil 124 6 4.8 4 66.7 0 —
Masanja et al. 2003 Tanzania 153 66 43.1 37 56.1 0 —
Hyan et al. 2004 Australia 30 30 — 30 — 6 20.0%
Kokemueller et al. 2004 German 155 90 58.1 90 — 7 7.8
Poomsawat et al. 2004 Thailand 60 54 90.0 37 68.5 1 2.7
Strick 2004 England 21 21 — 21 — 5 23.8
Toida et al. 2004 Japan 82 82 — 27 32.9 0 —
Vuhahula 2004 Uganda 268 88 32.8 47 53.4 7 14.9
Lima et al. 2005 Brazil 245 46 18.8 22 47.8 0 —
Ito et al. 2005 Brazil 496 113 22.8 53 46.9 9 17.0
Luukkaa et al. 2005 Finland 46 46 — 46 — 8 17.4
Otho et al. 2005 Niger 79 33 41.8 14 42.4 0 —
Yih et al. 2005 USA 213 213 — 94 44.1 18 19.1
Ascani et al. 2006 Italy 454 30 6.6 7 23.3 0 —
Ansari et al. 2007 Iran 130 18 13.8 16 88.9 0 —
Buchner et al. 2007 USA 380 380 — 156 41.1 27 17.3
Jones et al. 2007 England 741 455 61.4 172 37.8 28 16.3
Ladeinde et al. 2007 Niger 120 76 63.3 52 68.4 5 9.6
Pires et al. 2007 USA 546 546 — 241 44.1 28 11.6
Wang et al. 2007 China 737 737 — 397 — 34 8.6
Copeli et al. 2008 Italy 43 43 — 43 — 1 2.3
Li et al. 2008 China 3,461 914 26.4 539 59.0 1 0.2
Rahman et al. 2008 Paquistan 70 70 — 70 — 2 2.9
Subhashraj et al. 2008 India 684 150 21.9 59 39.3 0 —
Chijiwa et al. 2009 Japan 22 22 — 22 — 0 —
Dhanuthai 2009 Thailand 311 311 — 164 52.7 2 1.2
Gao et al. 2009 China 1,062 519 48.9 519 — 19 3.7
Mucke et al. 2009 German 95 95 — 95 — 14 14.7
Ochicha et al. 2009 Niger 78 19 24.4 7 36.8 2 28.6
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The tumor is characterized by single-layer strands of
cells that can form lobular, tubular, cribriform, trabecu-
lar, papillary-cystic and cystic histological patterns,
which can be illustrated by the presence of extracellular
matrix between the strands of cells identified in lobular
or solid patterns [7].
Most PLGA cells are cytologically uniform and range
from small to medium in size, with vesicular oval nuclei
and inconspicuous nucleoli. Their cytoplasm is ample
and exhibits a variable appearance, including eosino-
philic, basophilic and clear aspects. The cells have indis-
tinct outlines that lend a syncytial pattern to the active
cellular mass. Groups of cells with a coarsely eosino-
philic granular cytoplasm, mimicking oncocytes, are oc-
casionally observed, as are mucous cells [1,8].
The cells show a unique electron microscopy and
immunohistochemical phenotype. All cells have micro-
villi apically and are attached to the basal lamina. The
cells are positive for vimentin, CK 7 and S100, a pattern
only shared by the mammary analogue secretory carcin-
oma, as recently described by Skalova et al. and rarely by
focal plasmacytoid cells in pleomorphic adenoma [8-10].
A regular distribution of positive staining for β1, β2 and
β3 integrins and striking bipolar staining in all of the
neoplastic cells reinforces this unique phenotype [11].
Single cells, usually infiltrating surrounding structures,
and clear cells in nests are also observed in the lobular
PLGA subtype. The stroma appears either strongly eo-
sinophilic and hyalinized, or muco-hyalinized with a
bluish tint. Foci of residual salivary gland acini surrounded
by neoplastic cells are occasionally found. Peri-neural in-
vasion by groups of tumor cells is a frequent finding, and
psammoma-like structures are occasionally observed. This
tumor frequently presents with prominent vascularity [8].
Despite greater understanding of this tumor, PLGA
remains a diagnostic challenge for pathologists. This
conclusion is based on the variability of the epidemio-
logical results obtained by several groups who have stud-
ied this tumor.
We have reviewed the epidemiological studies in an at-
tempt to analyse the proportion of PLGAs in salivary
gland tumors.
Materials and methods
This analysis included 57 epidemiological studies of sal-
ivary gland tumors published in the English language
from 1992 to 2012. The year 1992 marked the inclusion
of PLGA in the World Health Organization (WHO)
classification of salivary gland tumors [12]. Studies were
included in the analysis if they contained the data
needed to calculate the fraction of PLGAs in the malig-
nant minor salivary gland tumor (MMSGT) total.
The studies addressing only major salivary gland tumors
were excluded because the few cases published on that
topic do not significantly contribute to the understanding
of PLGA; similarly, studies that included only children
and adolescents were excluded from this analysis.
When data were available, we extracted the following
information: total number of salivary gland tumors;
number of minor salivary gland tumors and their
Table 1 The distribution of salivary gland tumors, minor salivary gland tumors and polymorphous low-grade
adenocarcinoma in the studies included in this review (Continued)
Oliveira et al. 2009 Brazil 599 87 14.5 50 57.5 0 —
Targa-Stramandinoli et al. 2009 Brazil 14 14 — 7 50.0 1 14.3
Tilakaratne et al. 2009 Sri Lanka 713 486 68.2 276 56.8 27 9.8
Carrillo et al. 2010 Mexico 77 77 — 77 — 0 —
Erovic et al. 2010 Austria 32 32 — 32 — 0 —
Kakarala & Bhattacharyya 2010 USA 639 639 — 639 — 0 —
Kruse et al. 2010 Switzerland 27 27 — 27 — 0 —
Tian et al. 2010 China 6,982 1,977 28.3 1228 62.1 29 2.4
Bjorndal et al. 2011 Denmark 952 266 27.9 266 — 66 24.8
Morais et al. 2011 Brazil 303 37 12.2 26 70.3 3 11.5
Schwarz et al. 2011 German 41 41 — 41 — 8 19.5
Venkata et al. 2011 India 185 185 — 138 74.6 18 13.0
Bello et al. 2012 Finland 1,888 177 9.4 68 38.4 11 16.2
Bello et al. 2012 Israel 330 111 33.6 71 64.0 8 11.3
Luksic et al. 2012 Croatia 768 297 38.7 210 70.7 4 1.9
Total — — 26,960 11,079 41.1 6,891 62.2 431 6.3
SGTs: salivary gland tumors; MSGTs minor salivary gland tumors; MMSGTs: malignant minor salivary gland tumors; PLGA: polymorphous low-grade
adenocarcinoma.
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fraction of the total number of tumors; number of
MMSGTs and their fraction of the total number of
minor salivary gland tumors; number of PLGAs and
their fraction of the total number of MMSGTs; and the
total number of minor salivary gland tumors.
In this study, we analyzed the fraction of PLGAs in
the total number of MMSGTs. It was not possible to ob-
tain the absolute or relative frequencies of malignant sal-
ivary tumors, either among minor salivary tumors alone
or among major and minor tumors, from studies that
reported only MMSGTs.
Statistical analysis
Data were tabulated and descriptive statistics were calcu-
lated using frequency tables. G tests were used to ascertain
whether the PLGA fraction of all MMSGTs varied by the
year, country and continent in which the studies were per-
formed. We would like to emphasize that at no point was it
presumed that these studies reflect the prevalence of this
tumor with respect to the aforementioned variables (year,
country and continent). The significance level was set at 5%.
The statistical calculations were performed using the SPSS
20 software package (IBM corporation, Armonk, NY, USA).
Results
Fifty-seven surveys of salivary gland tumors were
included in this review (Table 1) [13-68]. From 26,960
cases of salivary gland tumors, 431 (1,6%) were accepted
by the authors as been PLGAs.
There has been a significant increase (p < 0.0001 for the
G test) in the fraction of PLGA cases reported in the lit-
erature since 2007, as shown in Table 2. Epidemiological
studies from 1992 to 1994 and 2001 to 2003 included no
reports of PLGAs, whilst 1.8% of the MMSGTs reported
from 1998 to 2000 were PLGAs. Higher percentages were
noted from 1995 to 1997 and 2007 to 2012. The highest
PLGA percentages were reported in the studies published
from 2004 to 2006 (Table 2).
The frequency of PLGA also varied significantly (p <
0.0001 for the G test) by country, as shown in Table 3.
Of the 431 PLGA cases included in this review (Table 1),
95 (22.0%) were from studies performed in the USA, 83
(19.3%) were from Chinese studies and 66 (15.3%) were
from Danish studies. The percentage of PLGAs among
MMSGTs varied among the studies, ranging from 0.0%
to 24.8% (Table 3).
The frequency of reported PLGA cases also varied sig-
nificantly (p < 0.0001) by the continent in which the
MMSGT studies were performed. The continent with
Table 2 The numbers and percentages of polymorphous
low-grade adenocarcinomas in malignant minor salivary
gland tumors by publication year as described in the
studies included in this review
Year MMSGTs PLGA PLGA/MMSGTs
n % n % %
1992-1994 146 2.1 0 0.0 0.0
1995-1997 341 4.9 29 6.7 8.5
1998-2000 163 2.4 3 0.7 1.8
2001-2003 45 0.7 0 0.0 0.0
2004-2006 488 7.1 61 14.2 12.5
2007-2009 2,885 41.9 191 44.3 6.6
2010-2012 2,823 41.0 147 34.1 5.2
Total 6,891 100.0 431 100.0 6.3
MMSGTs: malignant minor salivary gland tumors; PLGA: polymorphous low-
grade adenocarcinoma.
Table 3 The numbers and percentages of polymorphous
low-grade adenocarcinomas in malignant minor salivary
gland tumors by country as described in the studies
included in this review
Country MMSGTs PLGA PLGA/MMSGTs
n % n % %
Australia 30 0.4 6 1.4 20.0
Austria 32 0.5 0 0.0 0.0
Brazil 356 5.2 20 4.6 5.6
China 2,683 38.9 83 19.3 3.1
Croatia 210 3.0 4 0.9 1.9
Denmark 266 3.9 66 15.3 24.8
Ecuador 14 0.2 0 0.0 0.0
England 384 5.6 33 7.7 8.6
Finland 118 1.7 19 4.4 16.1
German 226 3.3 29 6.7 12.8
India 197 2.9 18 4.2 9.1
Iran 16 0.2 0 0.0 0.0
Israel 104 1.5 11 2.6 10.6
Italy 50 0.7 1 0.2 2.0
Japan 98 1.4 0 0.0 0.0
Jordan 20 0.3 0 0.0 0.0
Kenya 58 0.8 0 0.0 0.0
Mexico 77 1.1 0 0.0 0.0
Niger 73 1.1 7 1.6 9.6
Paquistan 70 1.0 2 0.5 2.9
Sri Lanka 276 4.0 27 6.3 9.8
Switzerland 27 0.4 0 0.0 0.0
Tanzania 37 0.5 0 0.0 0.0
Thailand 201 2.9 3 0.7 1.5
Uganda 47 0.7 7 1.6 14.9
USA 1,193 17.3 95 22.0 8.0
Venezuela 28 0.4 0 0.0 0.0
Total 6,891 100.0 431 100.0 6.3
MMSGTs: malignant minor salivary gland tumors; PLGA: polymorphous low-
grade adenocarcinoma.
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the highest reported frequency of PLGAs was Asia, with
3,702 of the 6,891 reported cases (53.7%), followed by
America (24.2%) and Europe (19.1%), as shown in
Table 4. The PLGA percentages also varied significantly
by continent, with frequencies ranging from 3.9% in Asia
to 20.0% in Oceania.
Discussion
Analysis of the data from 57 epidemiological studies
reflects a variety of methodologies, some examined all
(major and minor) salivary gland tumors, while others
examined only tumors of the minor glands but included
benign and malignant tumors or even MMSGTs alone.
This variability most likely reflects differences between
the institutions from where most of the data were col-
lected, such as hospitals and medical or dental schools.
In other words, it does not reflect the real epidemiology
of this tumor in these countries or continents, since they
are a few isolated reports.
Nevertheless, it was possible to discern the PLGA per-
centages among the MMSGT cases, which was the aim
of this study. We observed that PLGA rates have varied
over the period studied and have most recently
increased, most likely due to improved PLGA diagnostic
accuracy. Over the last two study periods, the PLGA
fraction has stabilized at a value that probably reflects a
more accurate percentage of PLGAs among MMSGTs.
We also noted that the percentage varied by the contin-
ent where the studies were performed and by individual
authors. Based on these results, we suggest that geograph-
ical differences alone cannot account for the varying inci-
dence rates, such as occurs with Warthin tumor, which
has a lower incidence in Africa, and with the lymphoe-
pithelial carcinoma that has an evident predilection for
Inuits (Eskimo), Chinese and Japanese [33,37,69,70]. Also
based on these differences it is impossible to extracting
other important data as the differences in ACC survival
rates between Chinese and occidental data as recently
demonstrated by Zhou et al. [71].
Despite our improved understanding of this entity over
time, worldwide differences found amongst the studies
indicate that diagnosing PLGA remains challenging,
probably because histological and cytological criteria are
not uniformly applied. Interestingly, this diagnosis does
not appear in some of the series, which used the desig-
nation “adenocarcinoma” with no further definition,
which raises the question of whether a tumor is actually
an adenocarcinoma NOS, a PLGA or another entity.
Since the 1990s, many studies have attempted to de-
velop a useful marker for PLGA or to differentiate it from
other histologically similar tumors [72-75]. To date there
has been no reliable molecular marker to distinguish
Table 4 The numbers and percentages of polymorphous
low-grade adenocarcinomas in malignant minor salivary
gland tumors by continent as described in the studies
included in this review as described in the studies
included in this review
Continent MMSGTs PLGA PLGA/MMSGTs
n % n % %
Africa 178 2.6% 14 3.2% 7.9%
America 1,668 24.2% 115 26.7% 6.9%
Asia 3,702 53.7% 144 33.4% 3.9%
Europe 1,313 19.1% 152 35.3% 11.6%
Oceania 30 0.4% 6 1.4% 20.0%
Total 6,891 100.0 431 100.0 6.3
MMSGTs: malignant minor salivary gland tumors; PLGA: polymorphous low-
grade adenocarcinoma.
Figure 1 The morphological and immunohistochemical aspects
of PLGA. 1A: H&E staining shows a tumor histology composed of
uniform single-cell strands. Diffuse and strong CK7 (1B) and vimentin
(1C) immunohistochemical positivity are shown.
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PLGA from other MMSGTs [76]. The major research
focus is currently on finding immunohistochemical differ-
ences between PLGA and adenoid cystic carcinoma
(ACC), mainly in the cribriform histology, common to
both tumors, which has been tirelessly attempted [77-87].
Controversy on this subject persists in the literature.
Some authors believe that immunohistochemistry does
not have any proven diagnostic value for identifying
PLGA [6,78,88,89]. However, we do not share this opin-
ion as we have successfully used immunohistochemistry
in difficult cases or to confirm a histological diagnosis.
For diagnostic purposes, it is essential to characterize
the morphology of the cell, the diversity of the histological
tumor patterns and to recall that the PLGA cellular popu-
lation exhibits a constant cytological appearance, despite a
variety of growth patterns.
In our experience it is important to note that tumor cy-
tology and histology are usually sufficient for a final diag-
nosis. However, immunohistochemistry is valuable in
unclear PLGA cases, however. Uniformly positive vimen-
tin and CK 7 staining, except for the rare two-layer ducts,
is sufficient for a final PLGA diagnosis (Figure 1). S100 is
also positive in almost all of the cells, but this characteris-
tic is only diagnostically supportive. When examining
cytoskeleton filaments in salivary gland tumors, it is also
important to observe which cells are positive for each pro-
tein, rather than simply indicating the percentage of
tumors in a series that are positive for each marker. Using
this information, the immunohistochemistry of the cyto-
skeleton filament contributes greatly to the diagnosis of
salivary gland tumors, especially PLGAs.
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